Unveiling the JETOUR T1’s “Exploration DNA” through South America’s Extreme Geography
Peru, Brazil, Jan. 25, 2026 (GLOBE NEWSWIRE) — Recently, JETOUR kicked off the third season of its “Wonder For JETOUR”…
Brand Post
Columbia University Names Jennifer L. Mnookin as Next President
NEW YORK, Jan. 25, 2026 /PRNewswire/ — Columbia University’s Board of Trustees has appointed Jennifer L. Mnookin, a nationally recognized legal…
From Humanoid Robots to AI Seating: VivaNova Debuts “Active Health” Tech at imm cologne 2026
COLOGNE, Germany, Jan. 25, 2026 (GLOBE NEWSWIRE) — As the prestigious imm cologne 2026—the global benchmark for home design and…
INVESTIGATION ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact…
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Beta Bionics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Beta Bionics To Contact…
INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Launches Investigation Into Wealthfront Following Post-IPO Stock Decline
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Wealthfront To Contact Him…
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds BellRing Brands Investors of Pending Class Action Lawsuit
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BellRing To Contact Him…
Tulip Innovation Patent Claims Against Sunwoda Batteries Expand to Include KTC Action
BUDAPEST, Hungary, Jan. 26, 2026 /PRNewswire/ — On 19 January 2026, the Korea Trade Commission (KTC) instituted a case based…
FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and…
FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and…
CenterPoint Energy Winter Storm Update: CenterPoint releases more than 500 contract frontline electric workers to support restoration efforts in other hard-hit areas of the country; more than 99 percent of customers maintained power through overnight winter weather
Download photos and videos of CenterPoint’s winter weather response efforts here Overall system operated as designed with few customer outages,…
European Business Leader Optimism Dips
Citizens and Business Leaders United in Calling for Europe’s Reinvention Time is running out for Europe: 96% of business leaders, supported…
↑